Chemical Compound

Cabotegravir

CAS Registry Number 1051375-10-0
Cabotegravir chemical structure
Primary Record

Cabotegravir

Note: Only for scientific research or as raw materials for production.

In stock
8,454 g
Purity
99.2 %
CAS
1051375-10-0

Compound Identifiers & Properties

CAS
1051375-10-0
PubChem CID
54713659
SMILES
C[C@H]1CO[C@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O
Canonical SMILES
C[C@H]1CO[C@@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12

Names & Synonyms

  • Cabotegravir
  • Apretude
  • cabotegravirum
  • 1051375-10-0
  • Vocabria
  • GSK744
  • Cabotegravir sodium
  • Apretude (TN)
  • Vocabria (TN)
  • GSK1265744
  • GSK744 LAP
  • GSK744 LA
  • GSK1265744A
  • UNII-HMH0132Z1Q
  • Cabotegravir (Standard)
  • Cabotegravir [USAN:INN]
  • Cabotegravir(GSK744)
  • GSK 744
  • RefChem:573195
  • GSK-1265744
  • HMH0132Z1Q
  • SureCN82803
  • Cabotegravir (GSK744, GSK1265744)
  • CABOTEGRAVIR [INN]
  • CABOTEGRAVIR [JAN]
  • GSK-1265744A
  • D08LDB
  • CABOTEGRAVIR [USAN]
  • Cabotegravir and rilpivirine
  • MFCD25976748
  • S/GSK1265744
  • SCHEMBL82803
  • GSK-744LA
  • CABOTEGRAVIR [WHO-DD]
  • C19H17F2N3O5
  • CHEBI:172944
  • Cabotegravir (JAN/USAN/INN)
  • orb1301075
  • Cabotegravir; GSK1265744
  • CHEMBL2403238
  • SCHEMBL29374458
  • GTPL11386
  • DTXSID50146982
  • GSK 1265744
  • S-265744
  • 744 LA
  • WCWSTNLSLKSJPK-LKFCYVNXSA-N
  • CABENUVA COMPONENT CABOTEGRAVIR
  • CABOTEGRAVIR [ORANGE BOOK]
  • GLXC-90529
  • AMY27899
  • BCP08631
  • EX-A2330
  • GSK744 (S/GSK1265744)
  • BDBM50492496
  • EBC-26970
  • HY-15592R
  • s7766
  • ZINC96927633
  • AKOS027253403
  • S/GSK-1265744
  • ACN-041362
  • Cabenuva (cabotegravir + rilpivirine)
  • CCG-268708
  • CS-5078
  • DB11751
  • CID11965164
  • NCGC00386434-02
  • AC-30895
  • AS-61279
  • CID 11965085
  • DA-71856
  • FD143198
  • HY-15592
  • S/GSK1265744; GSK744
  • SY099595
  • A8566
  • NS00073130
  • J3.144.828J
  • A16014
  • D10548
  • P14046
  • EN300-7388992
  • A902375
  • (3R,6S)-N-[(2,4-difluorophenyl)methyl]-10-hydroxy-6-methyl-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.03,7]trideca-9,12-diene-12-carboxamide
  • (3S,11AR)-N-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
  • CAB
  • Q15411012
  • B0084-463362
  • (3S,11aR)-N-((2,4-difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide
  • (3S,11aR)-N-((2,6-difluoropyridin-3-yl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide
  • (3s,11ar)-n-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
  • (3R,6S)-N-[(2,4-difluorophenyl)methyl]-10-hydroxy-6-methyl-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.0,3,7]trideca-9,12-diene-12-carboxamide
  • (3R,6S)-N-[(2,4-difluorophenyl)methyl]-10-hydroxy-6-methyl-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.0?,?]trideca-9,12-diene-12-carboxamide
  • (3S)-N-(2,4-Difluorobenzyl)-2,3,4,6,9,9aalpha-hexahydro-5-hydroxy-3-methyl-4,6-dioxo-1-oxa-3a,8a-diaza-1H-benzo[f]indene-7-carboxamide
  • (3S,11AR)-3-METHYL-5,7-DIOXO-2,3,5,7,11,11A-HEXAHYDROOXAZOLO[3,2-A]PYRIDO[1,2-D]PYRAZINE-8-CARBOXYLIC ACID
  • (3S,11aR)-N-((2,4-Difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide
  • (3S,11aR)-N-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
  • (3S,11aR)-N-[(2,4-Difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8 -carboxamide
  • (3S,11aR)-N-[(2,4-Difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxooxazolo[3,2-a]pyrido[1,2- d]pyrazine-8-carboxamide; (3s,11Ar)-n-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2- d]pyrazine-8-carboxamide; Apretude; GSK 1265744A; GSK 744; (3S,11aR)-N-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
  • (3S,11aR)-N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,11,11a-tetrahydrooxazolo[[?]]pyrido[[?]]pyrazine-8-carboxamide
  • (3S,11aR)-N-[(2,4-Difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido [1,2-d]pyrazine-8-carboxamide
  • (3S,11aR)-N-[(2,4-Difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
  • 1264720-72-0
  • GSK-1265744|||(3S,11aR)-N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, (3S,11aR)Oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide|||S-265744
  • N-((2,4-difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide
  • N-(2,4-Difluorobenzyl)-3alpha-methyl-4,6-dioxo-5-hydroxy-2,3,4,6,9,9aalpha-hexahydro-1-oxa-3a,8a-diaza-1H-benzo[f]indene-7-carboxamide
  • OXAZOLO(3,2-A)PYRIDO(1,2-D)PYRAZINE-8-CARBOXAMIDE, N-((2,4-DIFLUOROPHENYL)METHYL)-2,3,5,7,11,11A-HEXAHYDRO-6-HYDROXY-3-METHYL-5,7-DIOXO-, (3S,11AR)-
  • Oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, (3S,11aR)-; (3S,11aR)-N-[(2,4-Difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide; (3s,11Ar)-n-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide; Cabotegravir; GSK 1265744A; GSK 744; GSK 1265744A
  • Oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, (3S,11aR)-;Oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, (3S,11aR)-